TY - JOUR
T1 - The future of MRI in radiation therapy
T2 - Challenges and opportunities for the MR community
AU - Goodburn, Rosie J.
AU - Philippens, Marielle E.P.
AU - Lefebvre, Thierry L.
AU - Khalifa, Aly
AU - Bruijnen, Tom
AU - Freedman, Joshua N.
AU - Waddington, David E.J.
AU - Younus, Eyesha
AU - Aliotta, Eric
AU - Meliadò, Gabriele
AU - Stanescu, Teo
AU - Bano, Wajiha
AU - Fatemi-Ardekani, Ali
AU - Wetscherek, Andreas
AU - Oelfke, Uwe
AU - van den Berg, Nico
AU - Mason, Ralph P.
AU - van Houdt, Petra J.
AU - Balter, James M.
AU - Gurney-Champion, Oliver J.
N1 - Funding Information:
Oliver J. Gurney‐Champion is supported by KWF Kankerbestrijding (Dutch Cancer Society) grant KWF‐UVA 2021‐13785. Ralph P. Mason is in part supported by National Institutes of Health P30 CA142543. NKI (Petra van Houdt), ICR (Uwe Oelfke, Rosie Goodburn, Wajiha Bano and Andreas Wetscherek) and UMC Utrecht (Marielle E.P. Philippens, Nico van den Berg and Tom Bruijnen) are part of the Elekta MR‐Linac Research Consortium. Joshua Freedman is an employee of Elekta. David. E.J. Waddington is supported by the Cancer Institute NSW (ECF/1015). Andreas Wetscherek and Uwe Oelfke are supported by a Cancer Research UK programme grant (C33589/A28284). We thank Dr. Joan Chick (The Royal Marsden NHS Foundation Trust) for providing medical images used in the figures.
Funding Information:
information Cancer Institute NSW, Grant/Award Number: ECF/1015; Cancer Research UK, Grant/Award Number: C33589/A28284; KWF Kankerbestrijding, Grant/Award Number: KWF-UVA 2021-13785; National Institutes of Health, Grant/Award Number: P30 CA142543Oliver J. Gurney-Champion is supported by KWF Kankerbestrijding (Dutch Cancer Society) grant KWF-UVA 2021-13785. Ralph P. Mason is in part supported by National Institutes of Health P30 CA142543. NKI (Petra van Houdt), ICR (Uwe Oelfke, Rosie Goodburn, Wajiha Bano and Andreas Wetscherek) and UMC Utrecht (Marielle E.P. Philippens, Nico van den Berg and Tom Bruijnen) are part of the Elekta MR-Linac Research Consortium. Joshua Freedman is an employee of Elekta. David. E.J. Waddington is supported by the Cancer Institute NSW (ECF/1015). Andreas Wetscherek and Uwe Oelfke are supported by a Cancer Research UK programme grant (C33589/A28284). We thank Dr. Joan Chick (The Royal Marsden NHS Foundation Trust) for providing medical images used in the figures.
Publisher Copyright:
© 2022 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
PY - 2022/12
Y1 - 2022/12
N2 - Radiation therapy is a major component of cancer treatment pathways worldwide. The main aim of this treatment is to achieve tumor control through the delivery of ionizing radiation while preserving healthy tissues for minimal radiation toxicity. Because radiation therapy relies on accurate localization of the target and surrounding tissues, imaging plays a crucial role throughout the treatment chain. In the treatment planning phase, radiological images are essential for defining target volumes and organs-at-risk, as well as providing elemental composition (e.g., electron density) information for radiation dose calculations. At treatment, onboard imaging informs patient setup and could be used to guide radiation dose placement for sites affected by motion. Imaging is also an important tool for treatment response assessment and treatment plan adaptation. MRI, with its excellent soft tissue contrast and capacity to probe functional tissue properties, holds great untapped potential for transforming treatment paradigms in radiation therapy. The MR in Radiation Therapy ISMRM Study Group was established to provide a forum within the MR community to discuss the unmet needs and fuel opportunities for further advancement of MRI for radiation therapy applications. During the summer of 2021, the study group organized its first virtual workshop, attended by a diverse international group of clinicians, scientists, and clinical physicists, to explore our predictions for the future of MRI in radiation therapy for the next 25 years. This article reviews the main findings from the event and considers the opportunities and challenges of reaching our vision for the future in this expanding field.
AB - Radiation therapy is a major component of cancer treatment pathways worldwide. The main aim of this treatment is to achieve tumor control through the delivery of ionizing radiation while preserving healthy tissues for minimal radiation toxicity. Because radiation therapy relies on accurate localization of the target and surrounding tissues, imaging plays a crucial role throughout the treatment chain. In the treatment planning phase, radiological images are essential for defining target volumes and organs-at-risk, as well as providing elemental composition (e.g., electron density) information for radiation dose calculations. At treatment, onboard imaging informs patient setup and could be used to guide radiation dose placement for sites affected by motion. Imaging is also an important tool for treatment response assessment and treatment plan adaptation. MRI, with its excellent soft tissue contrast and capacity to probe functional tissue properties, holds great untapped potential for transforming treatment paradigms in radiation therapy. The MR in Radiation Therapy ISMRM Study Group was established to provide a forum within the MR community to discuss the unmet needs and fuel opportunities for further advancement of MRI for radiation therapy applications. During the summer of 2021, the study group organized its first virtual workshop, attended by a diverse international group of clinicians, scientists, and clinical physicists, to explore our predictions for the future of MRI in radiation therapy for the next 25 years. This article reviews the main findings from the event and considers the opportunities and challenges of reaching our vision for the future in this expanding field.
KW - future
KW - ISMRM workshop
KW - MR
KW - radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=85138337199&partnerID=8YFLogxK
U2 - 10.1002/mrm.29450
DO - 10.1002/mrm.29450
M3 - Review article
C2 - 36128894
AN - SCOPUS:85138337199
SN - 0740-3194
VL - 88
SP - 2592
EP - 2608
JO - Magnetic Resonance in Medicine
JF - Magnetic Resonance in Medicine
IS - 6
ER -